AMRN unilaterally changing the label and claiming the label based on the Reduce-It results is truthful and non-misleading information. Its nuclear and risky and a last resort following a CRL but I like it... if the FDA conducts itself badly enough and say overrules their own ad-com I think it will holdup in court. Best to keep it in reserve until then.
News 
Market Data 
Discover 
